keyword
MENU ▼
Read by QxMD icon Read
search

pancreatic tumour

keyword
https://www.readbyqxmd.com/read/29778250/surgical-management-of-intraductal-papillary-mucinous-neoplasm-with-main-duct-involvement-an-international-expert-survey-and-case-vignette-study
#1
Lianne Scholten, Nadine C M van Huijgevoort, Marco J Bruno, Carlos Fernandez-Del Castillo, Sohei Satoi, Alain Sauvanet, Christopher Wolfgang, Paul Fockens, Suresh T Chari, Marco Del Chiaro, Jeanin E van Hooft, Marc G Besselink
BACKGROUND: The risk of invasive cancer in resected intraductal papillary mucinous neoplasm with main pancreatic duct involvement is 33%-60%. Most guidelines, therefore, advise resection of main duct intraductal papillary mucinous neoplasm and mixed type intraductal papillary mucinous neoplasm in surgically fit patients, although advice on the surgical strategy (partial or total pancreatectomy) differs. We performed a survey amongst international experts to guide the design of future studies and help to prepare for a single international set of guidelines...
May 16, 2018: Surgery
https://www.readbyqxmd.com/read/29777189/pancreatic-cancer-foiled-by-a-switch-of-tumour-subtype
#2
Fieke Froeling, David Tuveson
No abstract text is available yet for this article.
May 2018: Nature
https://www.readbyqxmd.com/read/29770302/percutaneous-microwave-thermosphere-ablation-of-pancreatic-tumours
#3
Anna Maria Ierardi, Pierpaolo Biondetti, Andrea Coppola, Enrico Maria Fumarola, Alberto Magenta Biasina, Salvatore Alessio Angileri, Gianpaolo Carrafiello
Background: In oncologic field, thermo-ablative procedures have spread more and more. Percutaneous microwave ablation (MWA) showed same benefits and some advantages over radiofrequency ablation (RFA). To date, a disadvantage of both was the not totally predictable size and shape of ablation volume. The aim of this study was to assess feasibility and safety of MWA in nonresectable pancreatic head cancer using a new technology of MW with high power (100 W) and frequency of 2,450 MH. Methods: Five patients with pancreatic head cancer treated with percutaneous MWA under ultrasound guidance were retrospectively reviewed...
April 2018: Gland Surgery
https://www.readbyqxmd.com/read/29769293/emerging-multitarget-tyrosine-kinase-inhibitors-in-the-treatment-of-neuroendocrine-neoplasms
#4
Federica Grillo, Tullio Florio, Francesco Ferraù, Elda Kara, Giuseppe Fanciulli, Antongiulio Faggiano, Annamaria A L Colao
In the last few years, the therapeutic approach for neuroendocrine neoplasms (NENs) has changed dramatically following the approval of several novel targeted treatments. The multi-target tyrosine kinase inhibitor (MTKI), sunitinib malate, has been approved by regulatory agencies in pancreatic NENs. The MTKI class, however, includes several other molecules (approved for other conditions), which are currently being studied in NENs. An in depth review on the studies published on the following MTKIs in neuroendocrine tumours: axitinib, cabozantinib, famitinib, lenvatinib, nintedanib, pazopanib, sorafenib and sulfatinib was performed...
May 16, 2018: Endocrine-related Cancer
https://www.readbyqxmd.com/read/29763628/whole-snake-venoms-cytotoxic-anti-metastatic-and-antiangiogenic-properties
#5
Harald Kerkkamp, Christoph Bagowski, Jeroen Kool, Babette van Soolingen, Freek Vonk, Daniëlle Vlecken
Currently, biological and organic substances are screened in order to find a new generation of therapeutics active against cancer. Previous research has identified promising candidate peptides in snake venom. In this study, venoms from different snake species (Naja annulifera, Naja kaouthia, Ophiophagus hannah and Echis carinatus) were screened for potential anti-cancer properties using pancreatic tumour cells as the assay system. The cells were incubated with venom and then subjected to the following analyses: (i) in vitro cell death (ii) in vitro migration (iii) in vivo dissemination and (iv) in vivo angiogenesis...
May 12, 2018: Toxicon: Official Journal of the International Society on Toxinology
https://www.readbyqxmd.com/read/29756486/osteonectin-as-a-screening-marker-for-pancreatic-cancer-a-prospective-study
#6
Angeliki Papapanagiotou, George Sgourakis, Kyriakos Karkoulias, Dimitris Raptis, Edward Parkin, Pantelis Brotzakis, Sanjay Panchal, Athanasios G Papavassiliou
Objective Osteonectin plays a central role in various processes during the development of pancreatic adenocarcinoma. This prospective pilot study was performed to determine the feasibility of serum osteonectin as a screening tool for pancreatic cancer. Methods Blood samples were collected from 15 consecutive patients with newly diagnosed pancreatic cancer and 30 matched healthy controls. Serum osteonectin was measured using an osteonectin enzyme-linked immunosorbent assay kit. The primary outcomes were the diagnostic performance of serum osteonectin and the threshold value for differentiation of patients from controls...
January 1, 2018: Journal of International Medical Research
https://www.readbyqxmd.com/read/29756206/phase-i-ii-trial-of-pimasertib-plus-gemcitabine-in-patients-with-metastatic-pancreatic-cancer
#7
Eric Van Cutsem, Manuel Hidalgo, Jean-Luc Canon, Teresa Macarulla, Igor Bazin, Elena Poddubskaya, Nebojsa Manojlovic, Dejan Radenkovic, Chris Verslype, Eric Raymond, Antonio Cubillo, Armin Schueler, Charles Zhao, Pascal Hammel
The selective MEK1/2 inhibitor pimasertib has shown anti-tumour activity in a pancreatic tumour model. This phase I/II, two-part trial was conducted in patients with metastatic pancreatic adenocarcinoma (mPaCa) (NCT01016483). In the phase I part, oral pimasertib was given once daily discontinuously (5 days on/2 days off treatment) or twice daily continuously (n = 53) combined with weekly gemcitabine (1,000 mg/m2 ) in 28-day cycles to identify the recommended phase II dose (RP2D) of pimasertib. In the phase II part, patients were randomised to pimasertib (RP2D) or placebo plus weekly gemcitabine (n = 88) to investigate progression-free survival (PFS), overall survival (OS) and safety...
May 14, 2018: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/29755112/tumour-buds-determine-prognosis-in-resected-pancreatic-ductal-adenocarcinoma
#8
Philipp Lohneis, Marianne Sinn, Fritz Klein, Sven Bischoff, Jana K Striefler, Lilianna Wislocka, Bruno V Sinn, Uwe Pelzer, Helmut Oettle, Hanno Riess, Carsten Denkert, Hendrik Bläker, Anja Jühling
BACKGROUND: The prognostic effect of tumour budding was retrospectively analysed in a cohort of 173 patients with resected pancreatic ductal adenocarcinomas (PDACs) of the prospective clinical multicentre CONKO-001 trial. METHODS: Haematoxylin and eosin (H&E)-stained whole tissue slides were evaluated. In two independent approaches, the mean number of tumour buds was analysed according to the consensus criteria in colorectal cancer, in one 0.785 mm2 field of view and additionally in 10 high-power fields (HPF) (HPF = 0...
May 14, 2018: British Journal of Cancer
https://www.readbyqxmd.com/read/29752349/paediatric-pancreatic-neuroendocrine-tumours-in-von-hippel-lindau-disease
#9
Samuel Matthew O'Toole, Anju Sahdev, Satya Bhattacharya, Roger Feakins, Evelien F Gevers, William Drake
Extract: Pancreatic neuroendocrine tumours (pNETs) are an established feature of von Hippel-Lindau disease (VHL), occurring in up to 17% of mutation carriers (Libutti et al. 2000; Blansfield et al. 2007; Erlic et al. 2010; Igarashi et al. 2014). The natural history of VHL-pNETs is poorly characterised with metastatic disease occurring in up to 25% of affected individuals (Erlic et al. 2010). Management of this unique pNET subgroup is complicated by the potential for multifocal and metachronous disease as well as extra-pancreatic VHL-related neoplasms (e...
May 11, 2018: Endocrine-related Cancer
https://www.readbyqxmd.com/read/29746922/diabetes-and-pancreatic-neuroendocrine-tumours-which-interplays-if-any
#10
REVIEW
Marco Gallo, Rosaria Maddalena Ruggeri, Giovanna Muscogiuri, Genoveffa Pizza, Antongiulio Faggiano, Annamaria Colao
Pancreatic neuroendocrine tumours (PanNETs) represent an uncommon type of pancreatic neoplasm, whose incidence is increasing worldwide. As per exocrine pancreatic cancer, a relationship seems to exist between PanNETs and glycaemic alterations. Diabetes mellitus (DM) or impaired glucose tolerance often occurs in PanNET patients as a consequence of hormonal hypersecretion by the tumour, specifically affecting glucose metabolism, or due to tumour mass effects. On the other hand, pre-existing DM may represent a risk factor for developing PanNETs and is likely to worsen the prognosis of such patients...
May 2, 2018: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/29739708/usefulness-of-combined-imaging-with-68-ga-dotatoc-pet-ct-and-spleen-scintigraphy-in-differentiating-a-neuroendocrine-tumour-of-the-pancreatic-tail-from-splenic-lesions-in-a-patient-with-posttraumatic-splenosis
#11
J Maffey-Steffan, C Uprimny, R Moncayo, A S Kroiss, I J Virgolini
No abstract text is available yet for this article.
May 5, 2018: Revista Española de Medicina Nuclear e Imagen Molecular
https://www.readbyqxmd.com/read/29738626/validation-of-at-least-1-mm-as-cut-off-for-resection-margins-for-pancreatic-adenocarcinoma-of-the-body-and-tail
#12
T Hank, U Hinz, I Tarantino, J Kaiser, W Niesen, F Bergmann, T Hackert, M W Büchler, O Strobel
BACKGROUND: The definition of resection margin (R) status in pancreatic cancer is under debate. Although a margin of at least 1 mm is an independent predictor of survival after resection for pancreatic head cancer, its relevance to pancreatic body and tail cancers remains unclear. This study aimed to validate R status based on a 1-mm tumour-free margin as a prognostic factor for resected adenocarcinoma involving the pancreatic body and tail. METHODS: Patients who underwent distal or total pancreatectomy for adenocarcinomas of the pancreatic body and tail between January 2006 and December 2014 were identified from a prospective database...
May 8, 2018: British Journal of Surgery
https://www.readbyqxmd.com/read/29737317/first-robotic-pylorus-preserving-pancreaticoduodenectomy-for-frantz-s-tumour-in-an-adolescent-girl
#13
Palanivelu Chinnusamy, Sumanta Dey, Bhushan Chittawadagi, Srivatsan Gurumurthy, Sandeep Sabnis, Senthilnathan Palanisamy
Solid pseudopapillary tumour (SPT) is one of the uncommon benign cystic neoplasms of pancreas occurring predominantly in young females. Being benign in nature, surgical resection is the treatment of choice with excellent 5-year survival. A 14-year-old girl presented with pain abdomen for 1 week. On evaluation, she was found to have a large SPT involving head and uncinate process of Pancreas She underwent robotic pylorus preserving pancreaticoduodenectomy (R-PPPD) with da Vinci® Si Robotic System (Intuitive Surgical, Sunnyvale, CA, USA)...
May 4, 2018: Journal of Minimal Access Surgery
https://www.readbyqxmd.com/read/29735503/immunoglobulin-g4-related-disease-of-the-paranasal-sinuses
#14
Anthony Bashyam, Sidhartha Nagala, Fawzia Tahir, Showkat Mirza
Immunoglobulin G4-related disease (IgG4-RD) is becoming increasingly documented. It was first described in relation to autoimmune pancreatitis. Features of the disease include tissue infiltration by IgG4 plasma cells with associated fibrosis and the growth of pseudotumours. A 71-year-old woman presented with increasing right cheek swelling and mild proptosis. Ten years earlier, she had a similar presentation and was diagnosed with an inflammatory pseudotumour. Examination revealed a lesion in the right nasal cavity...
May 7, 2018: BMJ Case Reports
https://www.readbyqxmd.com/read/29731998/development-of-novel-monoclonal-antibodies-against-cd109-overexpressed-in-human-pancreatic-cancer
#15
Gustavo A Arias-Pinilla, Angus G Dalgleish, Satvinder Mudan, Izhar Bagwan, Anthony J Walker, Helmout Modjtahedi
Pancreatic cancer is one of the most aggressive and lethal types of cancer, and more effective therapeutic agents are urgently needed. Overexpressed cell surface antigens are ideal targets for therapy with monoclonal antibody (mAb)-based drugs, but none have been approved for the treatment of pancreatic cancer. Here, we report development of two novel mouse mAbs, KU42.33C and KU43.13A, against the human pancreatic cancer cell line BxPC-3. Using ELISA, flow cytometry, competitive assay and immunoprecipitation followed by mass spectrometry, we discovered that these two mAbs target two distinct epitopes on the external domain of CD109 that are overexpressed by varying amounts in human pancreatic cancer cell lines...
April 13, 2018: Oncotarget
https://www.readbyqxmd.com/read/29720405/-smad4-dpc4
#16
REVIEW
Aoife J McCarthy, Runjan Chetty
Smad4 or DPC4 belongs to a family of signal transduction proteins that are phosphorylated and activated by transmembrane serine-threonine receptor kinases in response to transforming growth factor beta (TGF-β) signaling via several pathways. The gene acts as a tumour suppressor gene and inactivation of smad4/DPC4 is best recognised in pancreatic cancer. However, smad4/DPC4 is also mutated in other conditions and cancers such as juvenile polyposis syndrome with and without hereditary haemorrhagic telangiectasia, colorectal and prostate cancers...
May 2, 2018: Journal of Clinical Pathology
https://www.readbyqxmd.com/read/29720389/access-to-radical-resections-of-pancreatic-cancer-is-region-dependent-despite-the-public-healthcare-system-in-finland
#17
Reea Ahola, Heini Hölsä, Samuli Kiskola, Pirkka Ojala, Aino Pirttilä, Juhani Sand, Johanna Laukkarinen
BACKGROUND: Surgical resection is the best treatment option to improve the prognosis of pancreatic cancer (PC). Our aim was to analyse whether PC treatment strategies show regional variation in Finland, a country with a nationwide public healthcare system. METHODS: All patients diagnosed with PC in 2003 and 2008 were identified from the Finnish Cancer Registry. The data regarding tumour, treatment, demographics and timespans to treatment were recorded from the patient archives...
May 2, 2018: Journal of Epidemiology and Community Health
https://www.readbyqxmd.com/read/29718567/usefulness-of-dual-phase-cone-beam-computed-tomography-during-arteriography-and-automated-tumour-feeder-detection-software-in-transarterial-embolization-for-obscure-arterial-bleeding-in-the-abdomen
#18
Shiro Miyayama, Masashi Yamashiro, Keiichi Nagai, Natsuki Sugimori, Koji Iwata, Naoko Sakuragawa
We report the usefulness of dual-phase cone-beam computed tomography during angiography (CBCTA) and automated tumour-feeder detection software (AFD) in transarterial embolization (TAE) for three consecutive cases of obscure arterial bleeding in the abdomen. Two patients presented with lower gastrointestinal bleeding and one showed bleeding into the pancreatic pseudocyst. Superior mesenteric or common hepatic angiography did not demonstrate extravasation, but dual-phase CBCTA and AFD could identify extravasation and an access route to the bleeding point...
May 2, 2018: Journal of Medical Imaging and Radiation Oncology
https://www.readbyqxmd.com/read/29717230/therapeutic-developments-in-pancreatic-cancer-current-and-future-perspectives
#19
REVIEW
John P Neoptolemos, Jörg Kleeff, Patrick Michl, Eithne Costello, William Greenhalf, Daniel H Palmer
The overall 5-year survival for pancreatic cancer has changed little over the past few decades, and pancreatic cancer is predicted to be the second leading cause of cancer-related mortality in the next decade in Western countries. The past few years, however, have seen improvements in first-line and second-line palliative therapies and considerable progress in increasing survival with adjuvant treatment. The use of biomarkers to help define treatment and the potential of neoadjuvant therapies also offer opportunities to improve outcomes...
May 1, 2018: Nature Reviews. Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/29708592/meta-analysis-comparing-upfront-surgery-with-neoadjuvant-treatment-in-patients-with-resectable-or-borderline-resectable-pancreatic-cancer
#20
REVIEW
E Versteijne, J A Vogel, M G Besselink, O R C Busch, J W Wilmink, J G Daams, C H J van Eijck, B Groot Koerkamp, C R N Rasch, G van Tienhoven
BACKGROUND: Studies comparing upfront surgery with neoadjuvant treatment in pancreatic cancer may report only patients who underwent resection and so survival will be skewed. The aim of this study was to report survival by intention to treat in a comparison of upfront surgery versus neoadjuvant treatment in resectable or borderline resectable pancreatic cancer. METHODS: MEDLINE, Embase and the Cochrane Library were searched for studies reporting median overall survival by intention to treat in patients with resectable or borderline resectable pancreatic cancer treated with or without neoadjuvant treatment...
April 30, 2018: British Journal of Surgery
keyword
keyword
37704
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"